A traffic accident occurred on the morning of July 4 at the entrance to a hospital in the city of Luohe in China’s central Henan Province. During the incident, a NIO vehicle was suspected of operating out of control, knocking down many pedestrians on the roadside and causing significant damage.
On the same day, the Luohe Municipal Public Security Bureau issued a notice: “At 8:36 on July 4, 2022, a traffic accident occurred at the south gate of Luohe Central Hospital, resulting in six victims, of which one died following an unsuccessful rescue attempt, and the other five have suffered non life-threatening injuries. After a preliminary investigation, the driver of the accident was driving a small passenger car to visit a patient in the central hospital. Due to improper operation, the vehicle suddenly accelerated and collided with the vehicle in front, causing a traffic accident. At present, the driver of the accident has been arrested. Further investigation of the accident is underway.”
This is the second accident involving a vehicle made by NIO Inc. recently. At about 17:20 on June 22, a NIO test vehicle fell from the third floor of its headquarters in Shanghai, killing two digital cockpit testers, one of whom was a member of staff and the other a partner employee.
NIO Inc. announced on the same evening that after the accident, the company immediately cooperated with the public security department to start the investigation and analysis procedure of the cause of the accident. According to analysis of the field situation, it can be preliminarily confirmed that this was a human accident, and was not caused by the vehicle itself.
NIO, a brand of new energy vehicles, is currently selling well. On July 1, NIO announced its delivery volume in the month of June 2022 to be 12,961 vehicles, an increase of 60.3% year-on-year, reaching a new monthly delivery record. In the second quarter of 2022, NIO delivered a total of 25,059 new cars, up 14.4% year-on-year, with positive growth for nine consecutive quarters, exceeding its delivery guidelines for Q2 2022.